Abstract:

Objective To evaluate the efficacy of semaglutide in the treatment of overweight and obese adults with non⁃type 2 diabetes. Methods The randomized controlled trials（RCTs）of semaglutide versus placebo or other drugs in the treatment of overweight and obese adults with non⁃type 2 diabetes were retrieved from six data⁃ bases including the Cochrane Library，Embase，PubMed，CNKI，Wanfang data knowledge service platform and China biomedical literature service system as of April 2022. Revman 5.4.1 was applied to meta⁃analysis of RCTs that met the inclusion and exclusion criteria. Results Six RCTs were finally included，and 4137 adult patients with non⁃ type 2 diabetes were overweight and obese. The results of meta ⁃analysis showed that the percentage of decrease in body mass in semaglutide group was higher than that in placebo group and liraglutide group［MD = -12.87，95% CI （-14.28，-11.46），P < 0.05；MD = -7.18，95%CI（-10.95，-3.41），P < 0.05］；the decrease of body mass in sema⁃ glutide group was greater than that in placebo group and liraglutide group［MD = -12.58，95%CI（-14.07，-11.09）， P < 0.05；MD = -7.23，95%CI（-9.99，-4.48），P < 0.05］；the proportion of patients with ≥ 5%，≥ 10% and ≥ 15% decrease in body mass in semaglutide group was higher than that in placebo group and liraglutide group［OR = 8.90，95%CI（6.08，13.04），P < 0.05；OR = 3.59，95%CI（2.26，5.69），P < 0.05］，［OR = 12.45，95% CI（8.91， 17.39），P < 0.05；OR = 5.02，95%CI（2.56，9.84），P < 0.05］，［OR = 14.36，95% CI（9.39，21.96），P < 0.05； RR = 3.71，95%CI（2.57，5.34），P < 0.05］. Conclusion Semaglutide has significant weight loss effect in the treat⁃ ment of overweight and obese adults with non⁃type 2 diabetes，and is superior to liraglutide.

Key words: semaglutide,  , overweight,  , obesity,  , non?type 2 diabetes,  , Meta analysis